Frontiers in public health · 2026
People living with HIV co-infected with HBV at the Nkembo Outpatient Treatment Center, Gabon: prevalence and associated factors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moukanda-Ifoundou Rolf, Massolou-Outata Rachyda, Mangala Christian, Mombo-Maganga Christian, Matsomo-Kombet Gwladys Esmeralda, Boukandou-Bina Josiane Alda, Yenze-Mouelé Darly, Moutsinga Alain, Okolongo-Mayani Serge Christian, Maulot-Bangola Denis, Ouambo Hervé, Fokam Joseph, Ongali Brice, Lemamy Guy Joseph
Аннотация
BACKGROUND: Hepatitis B virus (HBV) is a global public health problem that affects many people, including people living with HIV (PLHIV). In Gabon, HBV infection remains a concern among PLHIV. This study aimed to determine the prevalence of HBV and its associated risk factors among PLHIV at the Nkembo Outpatient Treatment Center in Gabon.
METHODS: This was a cross-sectional study conducted at the Nkembo Outpatient Treatment Center in Gabon from 25 March to 31 May 2024, involving 410 PLHIV. Blood samples (plasma) were collected for analysis. The OnSite HBV-5 Rapid Test was used to detect the HBs antigen and HBe antigen. CD4 + counting was performed using the BD FACSPresto™ system. The measurement of HBV and HIV viral loads was carried out using the QuantStudio™5 device, after performing extraction using GenoXtract® (version 1.0). Statistical analysis of the data was conducted using SPSS (version 21.0).
RESULTS: Among the 410 PLHIV, the seroprevalence of HBV was 10.5% (95% CI: 7.9-13.8). Alcohol intake (adjusted odds ratio (aOR) = 2.1, 95% CI:1.2-3.4, p = 0.006), elevated transaminases (aOR = 3.1, 95% CI:1.8-4.8, p = 0.0001), CD4 + count less than 200 cells/mm3 (aOR = 3.6, 95% CI: 2.2-5.8, p = 0.0001), HIV viral load greater than 1,000 copies/mL (aOR = 2.5, 95% CI: 1.4-4.4, p = 0.001), and being unvaccinated (aOR = 2.2 95% CI: 1.2-3.8 p = 0.011) were identified as risk factors associated with HBV infection among PLHIV.
CONCLUSION: The prevalence of HBV remains a concern among PLHIV. Therefore, HBV screening is strongly recommended to improve the management of PLHIV in order to reduce this burden of co-infection.
METHODS: This was a cross-sectional study conducted at the Nkembo Outpatient Treatment Center in Gabon from 25 March to 31 May 2024, involving 410 PLHIV. Blood samples (plasma) were collected for analysis. The OnSite HBV-5 Rapid Test was used to detect the HBs antigen and HBe antigen. CD4 + counting was performed using the BD FACSPresto™ system. The measurement of HBV and HIV viral loads was carried out using the QuantStudio™5 device, after performing extraction using GenoXtract® (version 1.0). Statistical analysis of the data was conducted using SPSS (version 21.0).
RESULTS: Among the 410 PLHIV, the seroprevalence of HBV was 10.5% (95% CI: 7.9-13.8). Alcohol intake (adjusted odds ratio (aOR) = 2.1, 95% CI:1.2-3.4, p = 0.006), elevated transaminases (aOR = 3.1, 95% CI:1.8-4.8, p = 0.0001), CD4 + count less than 200 cells/mm3 (aOR = 3.6, 95% CI: 2.2-5.8, p = 0.0001), HIV viral load greater than 1,000 copies/mL (aOR = 2.5, 95% CI: 1.4-4.4, p = 0.001), and being unvaccinated (aOR = 2.2 95% CI: 1.2-3.8 p = 0.011) were identified as risk factors associated with HBV infection among PLHIV.
CONCLUSION: The prevalence of HBV remains a concern among PLHIV. Therefore, HBV screening is strongly recommended to improve the management of PLHIV in order to reduce this burden of co-infection.